Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Cold-Shock-Primed Lactobacillus rhamnosus GG Extracellular Vesicles Restore Liver-Gut Axis Homeostasis Through Bile Acid Metabolic Reprogramming in MASLD.

Created on 16 Nov 2026

Authors

Lin Liu, Xueyan Liu, Hongru Kong, Bingzhou Guo, Yu Mou, Manxin Li, Hao Wang, Sihan Zhou, Guoen Li, Wei Li, Lei Huang

Published in

Journal of extracellular vesicles. Volume 15. Issue 11.

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is intricately linked to gut-liver axis dysfunction, wherein microbial dysbiosis, bile acid dysregulation, and impaired intestinal barrier function synergistically drive disease pathogenesis. Here, we developed a nanotherapeutic platform using Lactobacillus rhamnosus GG-derived extracellular vesicles (LGG-EVs). Cold-shock fermentation (28°C) doubled the EV yield without compromising bioactivity. Following intraperitoneal administration in high-fat diet (HFD)-induced MASLD mice, LGG-EVs preferentially accumulated in the liver, where they reestablished bile acid homeostasis through Pparα-mediated reprogramming of Cyp7a1 and Cyp7b1 expression, reduced hepatic steatosis by suppressing lipogenic gene programs, and attenuated inflammation via inhibition of NF-κB/MAPK signalling. This hepatic bile acid modulation subsequently alleviated intestinal bile acid accumulation, restored intestinal barrier integrity via upregulation of tight-junction proteins, and reduced intestinal permeability. These intestinal improvements were accompanied by restoration of gut microbiota composition, marked by enrichment of beneficial taxa such as Akkermansia, Muribaculaceae, and Lachnospiraceae_NK4A136, alongside reduction in the Firmicutes/Bacteroidota ratio. Collectively, by orchestrating bidirectional liver-gut axis repair-initiated by hepatic bile acid metabolic reprogramming and propagated through gut microbiota restoration and intestinal barrier reinforcement-cold-shock-enhanced LGG-EVs represent a safe, high-yield nanomedicine for MASLD therapy.

PMID:
43035378
Bibliographic data and abstract were imported from PubMed on 16 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 3
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement